| Identification | Back Directory | [Name]
3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2) | [CAS]
2226511-77-7 | [Synonyms]
3,6-DMAD dihydrochloride
3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2) | [Molecular Formula]
C22H32ClN5 | [MOL File]
2226511-77-7.mol | [Molecular Weight]
401.98 |
| Hazard Information | Back Directory | [Uses]
3,6-DMAD dihydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD dihydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD dihydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD dihydrochloride can be used for research of cancer[1][2]. | [in vivo]
3,6-DMAD dihydrochloride (10 mg/kg; i.p.; three times every 12 hours, for 84 hours; NOD Scid mice with RPMI 8226 xenograft) has inhibition of XBP1 splicing in vivo[1].
3,6-DMAD dihydrochloride (10 mg/kg; 24 h; i.p.; every 48 hours, for 12 days; NOD Scid mice with RPMI 8226 xenograft) suppresses multiple myeloma xenograft growth in vivo[1]. | Animal Model: | NOD Scid mice (4-6 weeks) with RPMI 8226 xenograft[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; three times every 12 hours, for 84 hours | | Result: | Inhibited XBP1-luciferase activity in NOD Scid mice with RPMI 8226 xenograft. |
| Animal Model: | NOD Scid mice (4-6 weeks) with RPMI 8226 xenograft[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; every 48 hours, for 12 days | | Result: | Inhibited tumor growth in NOD Scid mice with RPMI 8226 xenograft. |
| [References]
[1] Jiang D, et, al. Acridine Derivatives as Inhibitors of the IRE1α-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma. Mol Cancer Ther. 2016 Sep;15(9):2055-65. DOI:10.1158/1535-7163.MCT-15-1023
[2] De SY, et, al. SHP-2 specific deletion in macrophages accelerates pathological cardiac hypertrophy through promoting IRE1α-XBP1s pathway regulated by IL-6 secretion. Research Article. 2022 May 3. |
|
|